A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Public ClinicalTrials.gov record NCT04657991. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA
Study identification
- NCT ID
- NCT04657991
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 257 participants
Conditions and interventions
Conditions
Interventions
- Binimetinib Drug
- Encorafenib Drug
- Pembrolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 14, 2021
- Primary completion
- Jan 11, 2026
- Completion
- Aug 30, 2026
- Last update posted
- Apr 6, 2026
2021 – 2026
United States locations
- U.S. sites
- 17
- U.S. states
- 5
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Adventist Health System/Sunbelt, Inc. | Orlando | Florida | 32803 | — |
| AdventHealth Hematology and Oncology | Orlando | Florida | 32804 | — |
| AdventHealth Orlando Infusion Center | Orlando | Florida | 32804 | — |
| AdventHealth Orlando, Investigational Drug Services | Orlando | Florida | 32804 | — |
| The University of Kansas Clinical Research Center | Fairway | Kansas | 66205 | — |
| The University of Kansas Cancer Center - Overland Park | Overland Park | Kansas | 66210 | — |
| KU Eye Center | Prairie Village | Kansas | 66208 | — |
| The University of Kansas Cancer Center - Investigational Drug Services | Westwood | Kansas | 66205 | — |
| The University of Kansas Cancer Center | Westwood | Kansas | 66205 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Ophthalmic Consultants of Boston Inc (OCB) | Boston | Massachusetts | 02114 | — |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45219 | — |
| University of Cincinnati Medical Center | West Chester | Ohio | 45069 | — |
| West Chester Hospital | West Chester | Ohio | 45069 | — |
| University of Tennessee Medical Center | Knoxville | Tennessee | 37920 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 126 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04657991, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 6, 2026 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04657991 live on ClinicalTrials.gov.